

CLAIMS

What is claimed is:

1. A method for treating or preventing a cardiovascular disorder in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a tumor necrosis factor antagonist.
2. A method of Claim 1 wherein the cardiovascular disorder is selected from the group consisting of: acute myocardial infarction, deep vein thrombosis and thrombophlebitis.
3. A method of Claim 2 wherein the cardiovascular disorder is acute myocardial infarction.
4. A method for treating or preventing a cerebrovascular disorder in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a tumor necrosis factor antagonist.
5. A method of Claim 4 wherein the cerebrovascular disorder is stroke.
6. A method of treating or preventing a thrombotic disorder in an individual in need thereof comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the individual.
7. A method of Claim 6 wherein the thrombotic disorder is selected from the group consisting of: a thromboembolic disorder, a ischemic event, stroke,

acute myocardial infarction, deep vein thrombosis and thrombophlebitis.

8. A method of Claim 7 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.
9. A method of Claim 8 wherein the antibody is selected from the group consisting of: a chimeric antibody, a humanized antibody and a resurfaced antibody or fragment thereof.
10. A method of Claim 9 wherein the antibody binds to one or more amino acids of hTNF $\alpha$  selected from the group consisting of about 87-108 and about 59-80.
11. A method of Claim 9 wherein the antibody binds to the epitope of A2.
12. A method of Claim 9 wherein the antibody is a chimeric antibody.
13. A method of Claim 12 wherein the antibody binds to one or more amino acids of hTNF $\alpha$  selected from the group consisting of about 87-108 and about 59-80.
14. A method of Claim 12 wherein the antibody binds to the epitope of cA2.
15. A method of Claim 14 wherein the antibody is cA2.
16. A method of Claim 7 wherein the tumor necrosis factor antagonist is a receptor molecule, derivative or a fragment thereof which binds to tumor necrosis factor.

Sub B2

Sub B2

- sl 25  
au

[illegible]

- gl  
wb

consisting of about 87-108 and about 59-80.

sl  
a3

33. A method of Claim 32 wherein the antibody binds to the epitope of A2.

Sub  
B5

5 34. A method of Claim 31 wherein the antibody is a chimeric antibody.

35. A method of Claim 34 wherein the antibody binds to one or more amino acids of hTNF $\alpha$  selected from the group consisting of about 87-108 and about 59-80.

sl  
a6

10 36. A method of Claim 34 wherein the antibody binds to the epitope of cA2.

37. A method of Claim 36 wherein the antibody is cA2.

38. A method of Claim 29 wherein the tumor necrosis factor antagonist is a receptor molecule, derivative or a fragment thereof which binds to tumor necrosis factor.

15 39. A method of Claim 38 wherein the receptor molecule is selected from the group consisting of: p55 tumor necrosis factor receptor and p75 tumor necrosis factor receptor or functional portions thereof.

20 40. A method of Claim 38 wherein the receptor molecule is selected from the group consisting of: the extracellular domain of p55 tumor necrosis factor receptor and the extracellular domain of p75 tumor necrosis factor receptor.

25 41. A method of Claim 40 wherein the receptor molecule is a tumor necrosis factor receptor multimeric molecule.

42. A method of Claim 41 wherein the tumor necrosis factor receptor multimeric molecule comprises all or a functional portion of two or more extracellular domains of tumor necrosis factor receptors linked via one or more polypeptide linkers.
43. A method of Claim 40 wherein the receptor molecule is an immunoreceptor fusion molecule or functional portion thereof.
44. A method of Claim 43 wherein the immunoreceptor fusion molecule comprises all or a functional portion of a tumor necrosis factor receptor and an immunoglobulin chain.
45. A method of Claim 29 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis or tumor necrosis factor release.
46. A method of Claim 45 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.
47. A method of Claim 46 wherein the phosphodiesterase inhibitor is selected from the group consisting of: pentoxifylline and rolipram.
48. A method of Claim 45 wherein the tumor necrosis factor antagonist is selected from the group consisting of: thalidomide and tenidap.
49. A method of Claim 45 wherein the tumor necrosis factor antagonist is selected from the group consisting of: a A2b adenosine receptor agonist and a A2b adenosine receptor enhancer.

50. A method of Claim 29 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor receptor signalling.